Filtern
Dokumenttyp
- Posterpräsentation (5) (entfernen)
Referierte Publikation
- nein (5)
Schlagworte
- Antikörper (1)
- Arzneimittel (1)
- Diclofenac (1)
- ELISA (1)
- Haptenes (1)
- Haptensynthese (1)
- Monoclonal antibodies (1)
- Monoklonale Antikörper (1)
- Protein conjugates (1)
- Proteinkonjugate (1)
Organisationseinheit der BAM
Diclofenac (DCF) is a widely used drug against fever, inflammation, pain, and rheumatic diseases. An average of 70 % of the ingested diclofenac is excreted in the urine. Thus, 63 tons per year are introduced into the water cycle in Germany. Due to insufficient removal of diclofenac in wastewater treatment plants, residues of diclofenac can be found in surface water and sometimes in drinking water. In order to establish an immunoassay, an anti-DCF antibody was required. Some antibody developments have been reported, based on an immunogen resulting from direct coupling of diclofenac to proteins via the carboxylic function. Finally, we used a monoclonal antibody, clone F01G21.
Diclofenac is a widely used drug against fever, inflammation, pain, and rheumatic diseases. An average of 70 % of the ingested diclofenac is excreted in the urine. Thus, 63 tons are introduced into the water cycle in Germany. Due to insufficient removal of diclofenac in wastewater treatment plants, residues of diclofenac can be found in surface water and sometimes in drinking water It exist a polyclonal against diclofenac and monoclonal antibodies against diclofenac and it`s metabolites. There all based on direct couling of diclofenac on proteins via carboxylic functions. However it was imagined advantageous to introduce a heterobifunctional spacer between the analyte and the carrier protein.
Aceclofeac is commercial available. All other spacers can only be introduced with solid phase synthesis.